TAKE HUMAN HEALTH AS ITS MISSION AND DEVELOPMENT MOTIVATION
SOFTER IS AN ENTERPRISE WHOSE MAIN DEVELOPMENT DIRECTION IS MEDICAL DEVICE MANUFACTURING AND PHARMACEUTICAL R&D AND PRODUCTION
SOFTER BIOTECHNOLOGY
TAKE HUMAN HEALTH AS ITS MISSION AND DEVELOPMENT MOTIVATION
SOFTER IS AN ENTERPRISE WHOSE MAIN DEVELOPMENT DIRECTION IS MEDICAL DEVICE MANUFACTURING AND PHARMACEUTICAL R&D AND PRODUCTION
Medical Devices
SF-1, SF-2, SF-2, SF-2, Fugong, Gongjin stickers and blue boxes and other products, the main role of the product is to treat cervical diseases, repair and healing of cervical wounds. SF-1, SF-2, SF-2, SF-2, Fugong, Gongjin stickers and blue boxes and other products, the main role of the product is to treat cervical diseases, repair and healing of cervical wounds.
The "Chitosan Antibacterial Membrane" produced by Jiaxing Softer Biotechnology Co., Ltd. was developed by the China Center for Toxicology Drug Toxicology (World Health Organization Human Reproduction Research Cooperation Center) and has a new generation of biological products with original intellectual property rights. The core material of "Chitosan Antibacterial Film" is chitosan nano-iodine (chitoiodine), which is the core technology of the film. It is a complex of chitosan and iodine, and has the properties of chitosan and iodine.
Founded in 2009, it is a high-tech enterprise based on science and technology. It takes human health as its mission and development power, and medical device manufacturing, drug research and development and production as its main development direction. At present, the company is cooperating with Shanghai family planning scientific research institute and China Reproductive Regulation drug toxicology testing center of World Health Organization reproductive research center to research and produce biomedical materials for reproductive health and treatment of body diseases.
On the 3rd, the US FDA announced the approval of the listing of the CD38 antibody Sarclisa (isatuximab-irfc) developed by Sanofi (Sanofi) for use in combination with pomalidomide and dexamethasone to
With the continuous improvement of the medical security level of more than 1.3 billion people, my country's biomedical industry has huge market space. Compared with advanced countries in the world
The newly revised "Regulations for the Supervision and Administration of Medical Devices" (hereinafter referred to as the "Regulations") have been implemented since June 1, 2014. I
Editor's note: Recently, the National Health Commission responded to Recommendation No. 6238 of the First Session of the 13th National People's Congress. The reply stated that the National Hea